There were 604 press releases posted in the last 24 hours and 171,538 in the last 365 days.

SHAREHOLDER ALERT: SFMS Announces Filing of Securities Class Action Lawsuit Against Ocular Therapeutix, Inc.

/EIN News/ -- NEW YORK, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Shepherd, Finkelman, Miller & Shah, LLP (“SFMS”) announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey (Civil Action No. 17-05011) against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL) and certain of its officers and directors.  The case seeks remedies under the Securities Exchange Act of 1934 and is brought on behalf of a class consisting of all persons or entities that acquired Ocular securities between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”).  If you would like to discuss this action or have any questions regarding this notice or your rights, please contact either Bruce Parke (bparke@sfmslaw.com) or Jonathan Dilger (jdilger@sfmslaw.com); (866) 540-5505.

The Complaint alleges that, throughout the Class Period, Ocular made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing issues concerning the manufacture of its lead product, Dextenza, including that more than half the lots the Company produced contained bad product; (2) the foregoing issues could jeopardize Dextenza’s prospects of approval by the FDA; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN AN ATTORNEY. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS TIME. If you purchased or otherwise acquired Ocular securities during the Class Period, we encourage you to contact us with any questions prior to the September 5, 2017 lead plaintiff motion deadline.

SFMS is recognized as an accomplished firm in the areas of securities, corporate governance, antitrust and employee benefits litigation with offices in California, Connecticut, Florida, New Jersey, New York and Pennsylvania, as well as affiliate offices in London, England, and Milan, Italy.  SFMS has recovered hundreds of millions of dollars on behalf of investors.  For more information visit us at http://www.sfmslaw.com.

Contacts:

Bruce Parke
Jonathan Dilger
Shepherd Finkelman Miller & Shah, LLP
www.sfmslaw.com
Telephone: (866) 540-5504
Email: bparke@sfmslaw.com
jdilger@sfmslaw.com

Distribution channels: Law, Technology